EFG International AG Takes $802,000 Position in Illumina, Inc. $ILMN

EFG International AG bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 4,561 shares of the life sciences company’s stock, valued at approximately $802,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Primecap Management Co. CA acquired a new stake in shares of Illumina in the second quarter valued at approximately $617,981,000. Canada Pension Plan Investment Board acquired a new position in shares of Illumina during the 2nd quarter worth approximately $28,451,000. Legal & General Group Plc acquired a new position in shares of Illumina during the 2nd quarter worth approximately $206,299,000. The Manufacturers Life Insurance Company bought a new stake in Illumina in the 2nd quarter valued at $20,419,000. Finally, Fiduciary Financial Advisors bought a new stake in Illumina in the 2nd quarter valued at $26,000. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 1.3%

Shares of ILMN opened at $227.69 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $231.81. The firm’s 50 day moving average is $192.98 and its 200-day moving average is $155.18. The stock has a market capitalization of $34.38 billion, a PE ratio of 42.48, a P/E/G ratio of 3.16 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Activity

In other news, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the sale, the insider directly owned 20,338 shares in the company, valued at approximately $4,067,600. This represents a 2.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 2,034,688 shares of company stock worth $417,970,281. 2.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on ILMN. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. JPMorgan Chase & Co. raised their target price on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Citigroup lifted their target price on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a report on Monday, August 3rd. Finally, TD Cowen upped their price target on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Illumina presently has an average rating of “Hold” and a consensus target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.